Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009:4:245-51.
doi: 10.2147/copd.s4862. Epub 2009 Jul 20.

Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes

A Anzueto  1 , I Leimer, S Kesten
Affiliations

Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes

A Anzueto et al. Int J Chron Obstruct Pulmon Dis. 2009.

Abstract

Background: COPD exacerbations are responsible for the morbidity and mortality of this disease. The relationship between exacerbations and patient-related clinical outcomes is not clearly understood.

Methods: A retrospective analysis of two 1-year, placebo-controlled clinical trials with tiotropium 18 microg daily was conducted to examine relationships between exacerbations and other clinical outcomes. The relationship between FEV(1), St. George's Respiratory Questionnaire (SGRQ), and the transition dyspnea index (TDI) were examined based on the frequency of exacerbations (0, 1, 2, >2).

Results: 921 patients participated in the trials (mean age 65 years, mean FEV(1) = 1.02 L (39% predicted). The percent change from baseline in FEV(1) in the tiotropium group was +12.6%, +12.0%, +2.1% and +8.9%; and in the placebo group was -3.4%, -3.4%, -5.7% and -6.7% for exacerbation frequencies of 0, 1, 2, >2, respectively. Compared with baseline, the largest improvement in SGRQ occurred in patients with no exacerbations. In the placebo group, there was a significant association between an increased frequency of exacerbations and worsening SGRQ scores. A reduction in exacerbation rates of 4.4% to 42.0% such as that shown in this study cohort was associated with meaningful changes in questionnaire based instruments.

Conclusions: In the placebo-treated patients increased frequency of exacerbations was associated with larger decrements in FEV(1), TDI, and SGRQ. A reduction in the frequency of exacerbations is associated with changes that are considered meaningful in these clinical outcomes.

Keywords: FEV1; chronic obstructive pulmonary disease; dyspnea; exacerbations; quality of life.

PubMed Disclaimer

References

    1. Global Initiative for Chronic Obstructive Lung Disease. NHLBI/WHO workshop report. Bethesda: National Heart, Lung and Blood Institute; Apr, 2001. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Update November 2006, GOLD website. Available at: www.goldcopd.com. - PubMed
    1. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. MMWR. 2002;51:1–16. - PubMed
    1. Murray CGL, Lopez AD. Evidence-based health policy-lessons from the global burden of disease study. Science. 1996;274:740–743. - PubMed
    1. Friedman M, Witek TJ, Jr, Serby CW, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared to ipratropium alone and albuterol alone in chronic obstructive pulmonary disease. Chest. 1999;115:635–641. - PubMed
    1. National Heart, Lung, and Blood Institute. Morbidity and Mortality: 2002 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, Md: US Department of Health and Human Services, Public Health Service, National Institutes of Health; May, 2002.

MeSH terms